Compare Raytheon Technologies Corp (RTX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raytheon Technologies Corp vs Zoetis Inc — how do they compare? Raytheon Technologies Corp trades at $223.27 (market cap $301.71B), while Zoetis Inc trades at $74.9 (market cap $31.14B). The key difference: Raytheon Technologies Corp is far larger — about 9.7× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| RTX | ZTS | |
|---|---|---|
Market Cap | $301.71B | $31.14B |
Sector | Industrials | Health |
52-Week High | $224.12 | $156.76 |
52-Week Low | $151.75 | $71.91 |
Enterprise Value | $332.26B | $38.70B |
Dividend Yield | 1.3% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RTX trades at $224.12, up 0.49% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $223. Fundamentally, revenue grew to $88.6B in 2025 with net income of $6.73B, and recent contract wins like the $515M SPY-6 radar award bolster growth prospects. Earnings have consistently beaten estimates, with Q2 2026 EPS of $1.89 exceeding expectations.
The outlook is positive given robust defense spending and operational execution, but valuation multiples like a P/E of 39.41 pose risks if growth slows. Analyst consensus is bullish with a $233.14 price target, though overbought RSI levels suggest near-term consolidation may occur. Key risks include execution delays and macroeconomic pressures on defense budgets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
